Intuitive Investments Group PLC
LSE:IIG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Intuitive Investments Group PLC
Other Receivables
Intuitive Investments Group PLC
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intuitive Investments Group PLC
LSE:IIG
|
Other Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AdvancedAdvT Ltd
LSE:ADVT
|
Other Receivables
£355k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
National World PLC
LSE:NWOR
|
Other Receivables
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
abrdn European Logistics Income PLC
LSE:ASLI
|
Other Receivables
€6.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Literacy Capital PLC
LSE:BOOK
|
Other Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Schroder BSC Social Impact Trust PLC
LSE:SBSI
|
Other Receivables
£14k
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intuitive Investments Group PLC
Glance View
Intuitive Investments Group Plc is an investing company, which offers investment into life science company. The firm focuses on the life sciences sector. The firm's investment objective is to generate capital growth over the long term through investment in a portfolio concentrating on Life Sciences businesses operating predominantly in the United Kingdom, continental Europe and the United States. The firm invests in early and later-stage Life Sciences businesses. The company invests in the form of equity and equity-related instruments, including convertible debt instruments. The firm categories investment opportunities into four sub-sectors in Life Sciences: diagnostics, medical devices (Medtech), pharmaceuticals and biotechnology.
